Neko raises $700M to take preventive health scans to America

Neko Health is trying to turn preventive diagnostics into a repeatable consumer service rather than something people encounter only after symptoms appear. Its latest round gives it the capital to test that model in the US.

What happened

Neko Health raised a $700 million Series C led by Lightspeed and co-led by O.G. Venture Partners. Atomico, General Catalyst, Lakestar and several new investors also participated.

Founded by Daniel Ek and Hjalmar Nilsonne, the company operates clinics that provide a roughly one-hour health assessment using proprietary sensors, blood analysis and an in-person medical consultation. The scan is designed to collect a broad set of measurements without radiation and identify potential risk factors that may require follow-up.

Neko says more than 100,000 people have completed scans and that 75% prepay for another appointment. The company plans to use the new funding to expand internationally, including opening its first US clinic in New York.

Why it matters

Neko is not a pure software company. Its model combines physical clinics, medical staff, hardware, data systems and ongoing patient relationships. That makes the service harder to scale than a conventional digital-health app, but it may also create a more defensible product if customers value the full experience and return regularly.

The central question is whether the scans improve health outcomes, not simply whether they generate large volumes of data. Preventive screening can be valuable, but it can also produce false positives, unnecessary follow-up and higher downstream costs if the clinical pathway is not carefully designed.

The bigger picture

Healthcare startups are increasingly packaging diagnostics as consumer services. Neko’s funding suggests investors believe people will pay directly for earlier, more convenient health monitoring.

Its US expansion will be a major test of that thesis. The company must navigate a more fragmented healthcare system, stricter regulatory expectations and a competitive market while preserving clinical quality across a growing clinic network.